Inhibrx Biosciences (INBX) Enterprise Value
Price: $11.61
Market Cap: $168.07M
Avg Volume: 111.78K
Market Cap: $168.07M
Avg Volume: 111.78K
Country: US
Industry: Biotechnology
Sector: Healthcare
Industry: Biotechnology
Sector: Healthcare
Enterprise Value Summary (Quarterly)
According to Inhibrx Biosciences's latest quarterly financial reports:
- The enterprise value (EV) is 83.40M, which includes the market capitalization, debt, and subtracts cash and cash equivalents. EV provides a more comprehensive measure of a company's total value.
- The market capitalization is 227.95M, which is calculated by multiplying the current share price by the total number of outstanding shares.
- The stock price is $15.4, with 14.80M shares outstanding.
- The company has 152.60M in cash and cash equivalents and 8.05M in total debt.
Enterprise Value (EV) Formula:
EV = Market Cap + Total Debt - Cash and Cash Equivalents
Enterprise value is often used instead of market cap because it provides a more accurate valuation of a company by including debt and subtracting cash, giving a fuller picture of the company's total value.
Enterprise Value
$83.40M
Market Cap
$227.95M
Total Debt
$8.05M
Cash and Equivalents
$152.60M
Historical Enterprise Value
Inhibrx Biosciences Historical Enterprise Values
The table below shows various enterprise value metrics for each quarter, with the latest data available for 2024-12-31.
| Date | Enterprise Value | EV Change (%) | Stock Price | Number of Shares | Market Cap | Cash & Equivalents | Total Debt |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | $83.40M | 74.73% | $15.4 | 14.80M | $227.95M | $152.60M | $8.05M |
| September 30, 2024 | $47.73M | -285.08% | $15.66 | 15.47M | $242.23M | $196.33M | $1.83M |
| June 30, 2024 | $-25.79M | -101.39% | $13.74 | 14.48M | $198.90M | $226.86M | $2.17M |
| March 31, 2024 | $1.86B | -6.29% | $34.87 | 54.55M | $1.90B | $252.48M | $210.89M |
| December 31, 2023 | $1.99B | 170.65% | $38 | 54.03M | $2.05B | $277.92M | $210.14M |
| September 30, 2023 | $733.61M | -36.16% | $18.35 | 47.15M | $865.22M | $337.33M | $205.72M |
| June 30, 2023 | $1.15B | 45.22% | $25.96 | 43.64M | $1.13B | $192.49M | $208.61M |
| March 31, 2023 | $791.27M | -20.42% | $18.87 | 43.58M | $822.26M | $234.25M | $203.26M |
| December 31, 2022 | $994.33M | 36.61% | $24.64 | 43.27M | $1.07B | $273.87M | $202.07M |
| September 30, 2022 | $727.88M | 64.52% | $17.95 | 39.07M | $701.32M | $146.07M | $172.63M |
| June 30, 2022 | $442.42M | -47.41% | $11.35 | 39.04M | $443.10M | $176.38M | $175.70M |
| March 31, 2022 | $841.28M | -48.20% | $22.28 | 39.02M | $869.30M | $143.47M | $115.45M |
| December 31, 2021 | $1.62B | 32.39% | $43.67 | 38.58M | $1.68B | $131.30M | $70.47M |
| September 30, 2021 | $1.23B | 23.61% | $33.31 | 37.89M | $1.26B | $112.70M | $77.17M |
| June 30, 2021 | $992.34M | 44.52% | $27.52 | 37.82M | $1.04B | $125.73M | $77.15M |
| March 31, 2021 | $686.67M | -40.40% | $20.07 | 37.74M | $757.36M | $107.99M | $37.30M |
| December 31, 2020 | $1.15B | 215.20% | $32.97 | 37.71M | $1.24B | $128.66M | $37.45M |
| September 30, 2020 | $365.53M | -50.65% | $18 | 26.75M | $481.50M | $127.67M | $11.70M |
| June 30, 2020 | $740.70M | 16.97% | $20.63 | 35.65M | $735.55M | $5.63M | $10.78M |
| March 31, 2020 | $633.23M | 1.46% | $20.63 | 28.79M | $593.92M | $428.00K | $39.74M |
| December 31, 2019 | $624.11M | 5.08% | $20.63 | 28.79M | $593.92M | $11.54M | $41.73M |
| September 30, 2019 | $593.92M | -2.11% | $20.63 | 28.79M | $593.92M | $- | $- |
| June 30, 2019 | $606.72M | 0.40% | $20.63 | 28.79M | $593.92M | $27.62M | $40.42M |
| March 31, 2019 | $604.31M | 58.23% | $20.63 | 28.79M | $593.92M | $6.24M | $16.64M |
| December 31, 2018 | $381.92M | -35.70% | $20.63 | 18.15M | $374.53M | $2.10M | $9.49M |
| June 30, 2018 | $593.92M | -2.22% | $20.63 | 28.79M | $593.92M | $- | $- |
| March 31, 2018 | $607.39M | 61.66% | $20.63 | 28.79M | $593.92M | $-13.47M | $- |
| December 31, 2017 | $375.72M | - | $20.63 | 18.15M | $374.53M | $13.47M | $14.66M |
Related Metrics
Explore detailed financial metrics and analysis for INBX.